Epidemiology of HIV: Transmission, Demographics, and Prevention
This paper provides a comprehensive overview of the epidemiology of HIV (human immunodeficiency virus), examining the biological nature of the virus, its stages of progression, and the mechanisms by which it is transmitted. It discusses global and domestic demographic data, including the disproportionate burden carried by sub-Saharan Africa and challenges in measuring HIV prevalence and incidence. The paper also outlines treatment approaches such as pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and combination antiretroviral therapy (cART). The epidemiologic triangle and chain of infection are applied to contextualize HIV as a communicable disease, and the role of the CDC and community health nurses in surveillance and prevention is addressed.
- Description of HIV: Biology, progression, and stages of HIV infection
- HIV Transmission and Treatment: Transmission routes, treatment regimens, and viral load
- Epidemiologic Triangle and Chain of Infection: Public health frameworks applied to HIV
- Demographics of HIV: Global and U.S. HIV prevalence and incidence data
- The Role of the CDC in HIV Prevention: CDC programs, surveillance, and community health nursing
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Consistently grounds clinical definitions in accessible language, making technical terms such as CD4 cell count, viral load, and cART understandable to a broad audience.
- Moves logically from biological description to transmission mechanisms, then to population-level demographics and public health response, creating a coherent epidemiological narrative.
- Applies established public health frameworks — the epidemiologic triangle and chain of infection — directly to HIV, demonstrating analytical use of course concepts rather than mere description.
Key academic technique demonstrated
The paper demonstrates the application of the epidemiologic triangle (agent, host, and environment) and the chain of infection model to a specific communicable disease. Rather than simply listing facts, the author maps each element of these frameworks onto HIV, showing how theoretical public health tools are used to analyze real disease dynamics.
Structure breakdown
The paper opens with a clinical description of HIV, covering disease biology and progression. It then addresses transmission routes and treatment options before applying public health frameworks. A demographics section draws on WHO and CDC data to contextualize global and domestic burden. The paper closes with a discussion of the CDC's institutional role and the contribution of community health nurses to surveillance and care — moving from micro (viral biology) to macro (public health infrastructure).
Description of HIV
HIV — short for human immunodeficiency virus — is the viral infection that can lead to AIDS, or acquired immunodeficiency syndrome. The HIV virus remains in the body for life because the human body cannot rid itself of the virus; this is true even when the overt symptoms of HIV are absent (CDC, 2015). The virus spreads through specific bodily fluids and targets CD4 cells, also known as T cells, which are central to the body's immune system (CDC, 2015). Over time, HIV destroys enough CD4 cells to critically compromise the immune system, leaving the body incapable of fighting off infections and disease. This end stage of HIV infection is referred to as AIDS (CDC, 2015). Monitoring the CD4 cell count is therefore fundamental to managing the health of people living with HIV (CDC, 2015).
HIV progresses through several stages. The first stage is often — though not always — characterized by severe flu-like symptoms, including fever, sore throat, enlarged lymph nodes, and rash, occurring two to four weeks following exposure (CDC, 2015). It is important to note that many people infected with HIV experience no symptoms whatsoever for ten or more years. Even during the symptomatic phase shortly following exposure, carriers are highly infectious; however, the infection may not yet appear on an HIV test during this window period (CDC, 2015).
HIV Transmission and Treatment
HIV infection in the United States is predominantly the result of having sex with, or sharing injection drug equipment with, an HIV-infected person (CDC, 2015). For women living with HIV, transmission most frequently occurred through heterosexual sex with an HIV-infected man (80%), while for men living with HIV, transmission is predominantly the result of homosexual sex (85%) (CDC, 2015). Intravenous drug users may contract HIV by sharing needles, syringes, other equipment, and even rinse water. The bodily fluids known to transmit HIV include blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk (CDC, 2015). In order to transmit the virus, these fluids must come into contact with a mucous membrane or damaged tissue, or be directly injected into the bloodstream (CDC, 2015). Less common routes of transmission include passing the virus from mother to infant during pregnancy, birth, or breastfeeding, or receiving a blood transfusion or tissue/organ transplant contaminated with HIV (CDC, 2015).
Treatment of HIV has evolved considerably and currently includes pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) (CDC, 2015). PrEP is intended for people at high risk of contracting HIV and is used consistently as part of a daily regimen, often in combination with other preventive measures such as condoms (CDC, 2015). PEP is designed for use after a single high-risk exposure event to prevent HIV from replicating and spreading throughout the body. PEP must be initiated within three days of possible exposure and should ideally be started immediately (CDC, 2015).
Viral load is an important indicator of transmission risk. At undetectable levels, viral load can linger at 40 to 75 copies per milliliter of blood; as viral load climbs to millions of copies per milliliter, the risk of transmitting the virus to others increases significantly (CDC, 2015). Stopping medication, or acquiring an additional sexually transmitted disease (STD) or hepatitis infection, can increase the risk of spreading HIV by as much as three to five times compared to when HIV is the only active infection (CDC, 2015). Acquiring an STD causes viral load to rise and CD4 cell count to fall. When CD4 levels and viral load reach critical thresholds, individuals become susceptible to AIDS and to opportunistic illnesses such as pneumonia and certain cancers (CDC, 2015).
Treatment for people living with HIV includes antiretroviral therapy (ART) and highly active antiretroviral therapy (HAART), also known as combination antiretroviral therapy (cART), which indicates the use of two or more drug types simultaneously (CDC, 2015). cART regimens may include nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleotide reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase inhibitors — all of which interfere with the HIV infection and replication process at different stages (CDC, 2015).
Demographics of HIV
Since the AIDS epidemic began, nearly 78 million people have been infected with HIV, and approximately 39 million people have died of the disease (WHO, 2013). By the end of 2013, roughly 36.0 million people were living with HIV worldwide (WHO, 2013). The disease burden varies widely from country to country and region to region, but the global estimate is that approximately 0.8% of adults aged 15 to 49 are living with HIV (WHO, 2013). The sub-Saharan region of Africa is the most severely affected area globally — a region in which nearly one in every twenty adults lives with HIV (WHO, 2013). This figure represents nearly 71% of all people living with HIV worldwide (WHO, 2013).
Estimating the prevalence and incidence of HIV/AIDS is complicated by the fact that an average of ten years separates initial HIV infection from the development of AIDS (Osmond, 2003). This means that trend data for AIDS is understood through infection pattern data from approximately a decade earlier (Osmond, 2003). In order to gauge the effectiveness of measures to control the spread of HIV and to understand how the epidemic is progressing, stakeholders study HIV incidence rates (Osmond, 2003). Access to robust HIV incidence data is difficult to achieve, however, since small, locally conducted studies spread across the country are the primary sources of this information (Osmond, 2003).
Prevalence data is used to estimate the current national HIV disease burden and to forecast demand on systems providing medical care and social services for people living with HIV/AIDS (Osmond, 2003). Although prevalence data is more readily available than incidence data, it is important to recognize that no nationally representative surveillance system exists for prevalent infections (Osmond, 2003). Estimates of HIV prevalence must therefore rely on: (1) mathematical models utilizing reported AIDS cases; (2) serological surveys conducted by various sources; and (3) HIV infection reports from states that have laws requiring reporting of communicable diseases (Osmond, 2003). The quality and accuracy of prevalence data is naturally limited by the proportion and characteristics of people who seek HIV testing prior to receiving an AIDS diagnosis (Osmond, 2003). In effect, prevalence data provides a minimum estimate of the number of people living with HIV who have not yet developed AIDS, plus those reportedly living with AIDS (Osmond, 2003).
References
Osmond, D. H. (2003, March). Epidemiology of HIV/AIDS in the United States. HIV InSite Knowledge Base Chapter, University of California at San Francisco. Retrieved from http://hivinsite.ucsf.edu/InSite?page=kb-01-03#S2X
World Health Organization. (2013). Global Health Observatory (GHO) data. Retrieved from http://www.who.int/gho/hiv/en/
Centers for Disease Control and Prevention. (2012). Epidemiology of HIV infection through 2012. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Division of HIV/AIDS Prevention.
Centers for Disease Control and Prevention. (2015). HIV 101. Retrieved from
Create your account
Always verify citation format against your institution’s current style guide requirements.